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Dear Editor, 
We read with interest the paper by Martineau and colleagues on intrahepatic cholestasis of pregnancy 
(ICP) published online on January 7 2014 (1). We have also investigated pregnancy outcomes for women 
with ICP among 975,240 maternities in New South Wales (NSW), Australia. However unlike Martineau 
we did not find an increased risk of stillbirth. 
Briefly, we conducted a cohort study of all births of at least 20 weeks gestation or 400g birthweight 
(n=975,240) in NSW between 2001 and 2011, using linked routinely collected population health data 
from perinatal and hospital discharge data collections. ICP was identified in antenatal and birth hospital 
admission records by the diagnostic code O26.6 as classified in the International Classification of 
Diseases, 10th edition, Australian Modification. Logistic regression was used to calculate adjusted odds 
ratios for the association between maternal characteristics and pregnancy outcomes with ICP, with 
adjustment for age, plurality, parity, country of birth, maternal smoking in pregnancy, hospital maternity 
service level, pregnancy hypertension (gestational hypertension, preeclampsia or eclampsia) and 
gestational diabetes. These characteristics and outcomes have been validated against medical records 
and generally have high positive predictive values.      
ICP was diagnosed in 1870 maternities, including 1758 (0.19%) singleton maternities and 112 (0.73%) 
multiple (twins, triplets and quadruplets) maternities, giving an average incidence rate of 190 ICP 
diagnoses per 100,000 maternities. Women with ICP were more likely than women without ICP to be 
older (OR 1.14, 95% CI 0.91-1.43 for women ≥ 40 years), of high parity (OR 1.36, 95% CI 1.17-1.59 for 
parity ≥3 versus parity 1), smoke in pregnancy (OR 2.00, 95% CI 1.79-2.25), have a multiple gestation (OR 
3.47, 95% CI 2.86-4.21), and have gestational diabetes (OR 1.77, 95% CI 1.08-2.90, OR 1.70, 95% CI 1.45-
1.99 respectively) or pregnancy hypertension (OR 2.09, 95% CI 1.84-2.38) (p<0.0001 for all 
characteristics).  
There was no evidence for a difference in the odds of stillbirth (OR 0.72, 95% CI 0.40-1.31, p=0.28). 
However, there was strong evidence of the active management of ICP (Table 1), indicated by the higher 
odds of induction of labour (OR 3.12, 95% CI 2.84-3.42), caesarean section (OR 1.18, 95% CI 1.06-1.31) 
and planned preterm birth (OR 12.64, 95% CI 10.69-14.93). In addition, our study provides further 
evidence that ICP is associated with gestational diabetes (OR 1.70, 95% CI 1.45-1.99), pregnancy 
hypertension, spontaneous preterm birth and postpartum haemorrhage (1, 2). 
Consistent with other studies (2-4) conducted in the era of active management of ICP but in contrast to 
Martineau’s  case-control study (1), we found no increased risk of stillbirth in women diagnosed with 
ICP. However as we did not have data on serum bile acid levels, we could not determine ICP severity. It 
has recently been reported that amongst women with severe ICP (serum bile acid ≥40μmol/L) , there 
was a 3-fold increased risk of stillbirth despite active management (5). As there were only 3 stillbirths 
recorded in the 143 cases of ICP diagnosed in women in Martineau’s study (1), compared to 11 stillbirths 
in 1870 ICP-affected maternities in the current study, it is possible that the apparent increased risk of 
stillbirth despite active management of ICP reflects a chance finding due to small numbers rather than a 
true increased risk of stillbirth. Alternatively, there may be a higher prevalence of severe ICP in this 
population.  
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Table 1: Pregnancy outcomes associated with intrahepatic cholestasis of pregnancy (ICP) in 975,240 maternities 
in NSW, Australia, 2001-2011 
Pregnancy outcome ICP (%) No ICP (%) Crude OR (95% CI) Adjusted OR* (95% CI) p-value 
Planned birth         <0.001 
Spontaneous 
preterm 
140 (7.5) 36156 (3.7) 6.02 (4.94 - 7.33) 4.76 (3.89 - 5.83)  
Planned preterm 313 (16.7) 27541 (2.8) 17.66 (15.14 - 20.61) 12.64 (10.69 - 14.93)  
Spontaneous term 338 (18.1) 525309 (54.0) Ref  Ref   
Planned term 1079 (57.7) 384218 (39.5) 4.37 (3.86 - 4.93) 4.42 (3.90 - 3.5.01)  
Induction of Labour         <.0001 
No 922 (49.3) 736425 (75.7) Ref  Ref   
Yes 948 (50.7) 236799 (24.3) 3.20 (2.92 - 3.5) 3.12 (2.84 - 3.42)  
Mode of delivery         0.0005 
Normal vaginal 1046 (56.0) 588998 (60.5) Ref  Ref   
Instrumental 173 (9.3) 108347 (11.1) 0.90 (0.77 - 1.06) 0.89 (0.75 - 1.05)  
Caesarean section 650 (34.8) 275656 (28.3) 1.33 (1.2 - 1.47) 1.18 (1.06 - 1.31)  
Post partum 
haemorrhage 
        0.0025 
No 1678 (89.7) 900762 (92.6) Ref  Ref   
Yes 192 (10.3) 72319 (7.4) 1.43 (1.23 - 1.66) 1.26 (1.09 - 1.47)  
Stillbirth         0.28 
No 1857 (99.4) 967060 (99.4) Ref  Ref   
Yes 11 (0.6) 5838 (0.6) 0.98 (0.54 - 1.78) 0.72 (0.40 - 1.31)  
Gestational age         <.0001 
<37 weeks 453 (24.2) 909663 (93.5) 4.57 (4.11 - 5.08) 3.20 (2.84 - 3.59)  
≥37 weeks 1417 (75.8) 63707 (6.5) Ref  Ref   
Size for gestational 
age 
        0.57 
SGA 193 (10.3) 91356 (9.4) 1.12 (0.96 - 1.3) 0.98 (0.84 - 1.14)  
LGA 210 (11.2) 103661 (10.7) 1.08 (0.93 - 1.24) 1.08 (0.93 - 1.25)  
AGA 1466 (78.4) 777587 (80.0) Ref  Ref   
5 minute Apgar 
score 
        0.07 
<7 62 (3.3) 20883 (2.2) 1.56 (1.21 - 2.02) 1.27 (0.98 - 1.63)  
≥7  1808 (96.7) 952487 (97.9) Ref  Ref   
*Adjusted odds ratios for the association between intrahepatic cholestasis of pregnancy (ICP) were adjusted for 
age, plurality (singleton versus multiple), parity, country of birth, maternal smoking in pregnancy, maternal 
hypertension (chronic or gestational) and maternal diabetes (pre-existing or gestational).   
 
 
